10-Gingerol inhibits proliferation and invasion of MDA-MB-231 breast cancer cells through suppression of Akt and p38MAPK activity

Joo, Ji-Hye; Hong, Seong-Su; Cho, Young‐Rak; Seo, Dong‐Wan

doi:10.3892/or.2015.4405

Cited by 62 publications

(32 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These effects are mediated by EGFR and b1-integrin suppression. The results presented in this study are in agreement with previous studies demonstrating that [10]-gingerol presented antitumor activities in MDA-MB-231 breast cancer cells, which are mediated by EGFR suppression and inactivation of Akt and MAPK activities [Joo et al, 2016].…”

Section: Discussionsupporting

confidence: 93%

[10]-Gingerol Reverts Malignant Phenotype of Breast Cancer Cells in 3D Culture

et al. 2017

View full text Add to dashboard Cite

Breast cancer is a complex and multifactorial disease. Tumors have a heterogeneous microenvironment, which have multiple interactions with other cell types, greatly influencing the behavior of tumor cells and response to therapy. The 3D culture mimics the microenvironment better found in vivo and is more appropriated than the traditional 2D culture made from plastic to test the cellular response to drugs. To investigate the effects of [10]-gingerol on breast tumor cells, we used physiologically relevant three-dimensional (3D) cultures of malignant and non-malignant human breast cells grown in laminin-rich extracellular matrix gels (lr-ECM). Our results showed selective cytotoxicity of [10]-gingerol against the malignant T4-2 breast cancer cell line compared to non-malignant S1 cells. The compound reverted the malignant phenotype of the cancer cells, downregulating the expression of epidermal growth factor receptor (EGFR) and β1-integrin. Moreover, [10]-gingerol induced apoptosis in this cell line. These results suggest that [10]-gingerol may be an effective compound to use as adjuvant therapy in breast cancer treatment. J. Cell. Biochem. 118: 2693-2699, 2017. © 2017 Wiley Periodicals, Inc.

show abstract

Section: Discussionsupporting

confidence: 93%

[10]-Gingerol Reverts Malignant Phenotype of Breast Cancer Cells in 3D Culture

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In a syngenic mouse model of spontaneous breast cancer metastasis, gingerol (5 mg/ kg) treatment induced caspase-3 activation and inhibited the orthotopic tumor growth as well as metastasis of mouse brainmetastatic 4T1Br4 mammary tumor cells to multiple organs such as lung, bone and brain (Martin et al, 2017). Likewise, Joo and colleagues (Joo et al, 2016) reported inhibition of lungmetastatic, MDA-MB-231 human breast cancer cell proliferation, and invasion by [10]-gingerol through suppression of Akt, p38MAPK, and epidermal growth factor receptor. The detailed protective and therapeutic potential of gingerol in cancer is reviewed in de Lima et al (2018).…”

Section: Phytochemicals In Pre-clinical Trialsmentioning

confidence: 93%

Phytochemicals in Cancer Treatment: From Preclinical Studies to Clinical Practice

et al. 2020

View full text Add to dashboard Cite

Cancer is a severe health problem that continues to be a leading cause of death worldwide. Increasing knowledge of the molecular mechanisms underlying cancer progression has led to the development of a vast number of anticancer drugs. However, the use of chemically synthesized drugs has not significantly improved the overall survival rate over the past few decades. As a result, new strategies and novel chemoprevention agents are needed to complement current cancer therapies to improve efficiency. Naturally occurring compounds from plants known as phytochemicals, serve as vital resources for novel drugs and are also sources for cancer therapy. Some typical examples include taxol analogs, vinca alkaloids such as vincristine, vinblastine, and podophyllotoxin analogs. These phytochemicals often act via regulating molecular pathways which are implicated in growth and progression of cancer. The specific mechanisms include increasing antioxidant status, carcinogen inactivation, inhibiting proliferation, induction of cell cycle arrest and apoptosis; and regulation of the immune system. The primary objective of this review is to describe what we know to date of the active compounds in the natural products, along with their pharmacologic action and molecular or specific targets. Recent trends and gaps in phytochemical based anticancer drug discovery are also explored. The authors wish to expand the phytochemical research area not only for their scientific soundness but also for their potential druggability. Hence, the emphasis is given to information about anticancer phytochemicals which are evaluated at preclinical and clinical level.

show abstract

“…The inserts were fixed with methanol, and using a cotton‐tipped swab, the non‐invasive cells were removed from the top of the membrane. After staining with 0.04% Giemsa staining solution, the numbers of invasive cells (mean ± standard deviation) were determined from six different fields using ×200 objective magnification …”

Section: Methodsmentioning

confidence: 99%

Novel functions for 2‐phenylbenzimidazole‐5‐sulphonic acid: Inhibition of ovarian cancer cell responses and tumour angiogenesis

Kim

Ahn

et al. 2020

J Cellular Molecular Medi

View full text Add to dashboard Cite

In this study, we investigated the effects and molecular mechanisms of 2‐phenylbenzimidazole‐5‐sulphonic acid (PBSA), an ultraviolet B protecting agent used in sunscreen lotions and moisturizers, on ovarian cancer cell responses and tumour angiogenesis. PBSA treatment markedly blocked mitogen‐induced invasion through down‐regulation of matrix metalloproteinase (MMP) expression and activity in ovarian cancer SKOV‐3 cells. In addition, PBSA inhibited mitogen‐induced cell proliferation by suppression of cyclin‐dependent kinases (Cdks), but not cyclins, leading to pRb hypophosphorylation and G1 phase cell cycle arrest. These anti‐cancer activities of PBSA in ovarian cancer cell invasion and proliferation were mediated by the inhibition of mitogen‐activated protein kinase kinase 3/6‐p38 mitogen‐activated protein kinase (MKK3/6‐p38MAPK) activity and subsequent down‐regulation of MMP‐2, MMP‐9, Cdk4, Cdk2 and integrin β1, as evidenced by treatment with p38MAPK inhibitor SB203580. Furthermore, PBSA suppressed the expression and secretion of vascular endothelial growth factor in SKOV‐3 cells, leading to inhibition of capillary‐like tubular structures in vitro and angiogenic sprouting ex vivo. Taken together, our results demonstrate the pharmacological effects and molecular targets of PBSA on modulating ovarian cancer cell responses and tumour angiogenesis, and suggest further evaluation and development of PBSA as a promising chemotherapeutic agent for the treatment of ovarian cancer.

show abstract

10-Gingerol inhibits proliferation and invasion of MDA-MB-231 breast cancer cells through suppression of Akt and p38MAPK activity

Cited by 62 publications

References 35 publications

[10]-Gingerol Reverts Malignant Phenotype of Breast Cancer Cells in 3D Culture

[10]-Gingerol Reverts Malignant Phenotype of Breast Cancer Cells in 3D Culture

Phytochemicals in Cancer Treatment: From Preclinical Studies to Clinical Practice

Novel functions for 2‐phenylbenzimidazole‐5‐sulphonic acid: Inhibition of ovarian cancer cell responses and tumour angiogenesis

Contact Info

Product

Resources

About